证券代码：600222 证券简称：太龙药业 公告编号：2026-003 河南太龙药业股份有限公司 关于为下属控股子公司融资提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 本次担保金额 | 实际为其提供的 担保余额（含本次 | | 是否在前期预计 额度内 | 本次担保是否 有反担保 | | --- | --- | --- | --- | --- | --- | | | | 担保金额） | | | | | 郑州深蓝海生物医 药科技有限公司 | 300 万元 | 300 | 万元 | 是 | 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 29,703.37（含本次） | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 18.86 | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一 | ...

Core Viewpoint - The company has approved a profit distribution plan at the fourth extraordinary general meeting of shareholders on November 14, 2025, which includes a cash dividend distribution for the first three quarters of 2025 [1]. Distribution Plan - The distribution is based on a total share capital of 573,886,283 shares, with 20,961,800 shares in the company's repurchase account excluded, resulting in a base of 552,924,483 shares for the cash dividend distribution of 0.14 yuan per 10 shares (including tax), totaling 7,740,942.76 yuan (including tax) [2]. - The cash dividend per share is calculated to be approximately 0.0135 yuan after adjusting for the total share capital [2][4]. - The company will only distribute cash dividends without issuing new shares or capital reserve transfers, meaning there will be no change in the circulating shares [2]. Relevant Dates - The cash dividend distribution will be executed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch, with shareholders able to receive their dividends on the designated payment date [5]. Taxation Information - For individual shareholders holding unrestricted circulating shares, the tax treatment varies based on the holding period, with a maximum tax rate of 20% for shares held for one month or less, and a reduced rate of 10% for shares held between one month and one year [6]. - For Qualified Foreign Institutional Investors (QFII), a 10% corporate income tax will be withheld, resulting in a net cash dividend of 0.0126 yuan per share [7]. - Other institutional investors are responsible for their own tax obligations, with a cash dividend of 0.014 yuan per share [7].

证券代码：600222 证券简称：太龙药业 公告编号：临 2026-002 河南太龙药业股份有限公司 统一社会信用代码：91410000706786295N 分类码：AhztChDh 关于公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）近日收到河南 省药品监督管理局换发的《药品生产许可证》，同时对生产范围、生 产线及受托情况进行了变更，换发后的《药品生产许可证》有效期至 2030 年 12 月 31 日，现将相关情况公告如下： 一、换发后的《药品生产许可证》的相关情况 企业名称：河南太龙药业股份有限公司 许可证编号：豫 20150080 企业负责人：苏风山 住所（经营场所）：郑州高新技术产业开发区金梭路 8 号 法定代表人：王荣涛 质量负责人：李江华 生产负责人：张立壮 质量授权人：李江华 有效期至：2030 年 12 月 31 日 生产地址和生产范围： 证券代码：600222 证券简称：太龙药业 公告编号：临 2026-002 郑州高新技术产业开发 ...

Core Viewpoint - The company has received a renewed "Drug Production License" from the Henan Provincial Drug Administration, valid until December 31, 2030, which includes changes in production scope, production lines, and entrusted production situations [1] Group 1 - The renewal of the license ensures the company's normal operations and does not significantly impact the existing production structure [1] - The company will need to apply for GMP compliance checks to resume the production of certain products [1] - There are reductions in the production lines for certain products, including the reduction of the production of three drugs, such as Berberine Hydrochloride Tablets [1] Group 2 - The current changes do not affect the company's performance for this period, but there is uncertainty regarding drug production and sales due to policy and market influences [1]

证券代码：600222 证券简称：太龙药业 公告编号：2026-001 河南太龙药业股份有限公司 2025年前三季度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.014元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2026/1/8 | － | 2026/1/9 | 2026/1/9 | 差异化分红送转： 是 一、 通过分配方案的股东会届次和日期 （1）本次差异化分红方案 公司以实施权益分派股权登记日登记的总股本 573,886,283 股，扣减公司回购专用证券 账户中的 20,961,800 股，即 552,924,483 股为基数，向全体股东每 10 股派发现金红利 0.14 元（含税），共计派发现金红利 7,740,942.76 元（含税）。 （2）本次差异化分红除权除息的计算依据 根据《上海证券交易所交易规则》，公司按 ...

Group 1 - The core point of the article is that Tailong Pharmaceutical (600222.SH) announced a cash dividend distribution plan for the first three quarters of 2025, with a total cash dividend of 0.14 yuan per 10 shares, amounting to a total distribution of 7,740,942.76 yuan (including tax) [1] - The total share capital for the dividend distribution is 573,886,283 shares, from which 20,961,800 shares held in the company's repurchase account are deducted, resulting in a base of 552,924,483 shares for the distribution [1] - The record date for the dividend distribution is set for January 8, 2026, and the ex-dividend date is January 9, 2026 [1]

仟问律师事务所 CHAINWINLAWFIRM 关于河南太龙药业股份有限公司 差异化分红事项的 专项法律意见书 仟见字【2025】591 号 二〇二五年十一月 中国·河南 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 河南仟问律师事务所 专项法律意见书 仟 问 律 师 事 务 所 5F,12F,Huanhu International Plaza,189#Ping'an Ave,Zhengdong District,Zhengzhou CHAINWINLAWFIRM 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 5F,12F,Huanhu International Plaza,189#Ping'an Ave,Zhengdong District,Zhengzhou 网址(URL)：http://www.chainwinlaw.com 电邮(E-mail):qwlss@126.com 仟见字【2025】第591号 河南仟问律师事务所 关于河南太龙药业股份有限公司差异化分红事项的 专项法律意见书 致：河南太龙药业股份有限公司 河南仟问律师事务所接受河南太龙 ...

Core Viewpoint - The company announced a differentiated dividend distribution due to discrepancies between total share capital and shares eligible for distribution resulting from share buybacks in 2023 and 2025 [1] Group 1: Dividend Distribution - The company plans to distribute a cash dividend of 0.14 yuan (including tax) for every 10 shares to all shareholders, without issuing bonus shares or capitalizing reserves [1] - The total share capital as of the announcement date is 574 million shares, with 20.96 million shares deducted for the buyback account, leading to a proposed cash dividend payout of 7.7409 million yuan (including tax) [1] - The dividend amount represents 30.57% of the net profit attributable to shareholders for the first three quarters of 2025 [1] Group 2: Legal Compliance - Legal advisors believe that the dividend distribution complies with regulations and will have a minimal impact on the ex-dividend reference price [1]

Market Overview - The Chinese medicine sector experienced a decline of 0.3% on December 31, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Ziling: closed at 4.35, up 2.84% with a trading volume of 476,800 shares and a turnover of 207 million yuan [1] - Guohan Pharmaceutical: closed at 11.21, up 2.66% with a trading volume of 48,400 shares and a turnover of 54.01 million yuan [1] - Major decliners included: - *ST Changyao: closed at 0.87, down 8.42% with a trading volume of 828,300 shares and a turnover of 73.23 million yuan [2] - ST Huluwa: closed at 7.62, down 4.63% with a trading volume of 176,200 shares and a turnover of 134 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 399 million yuan from institutional investors, while retail investors contributed a net inflow of 376 million yuan [2] - The sector's capital flow details indicate: - Dong'e Ejiao had a net inflow of 27.6 million yuan from institutional investors, but a net outflow of 14.69 million yuan from speculative funds [3] - Guohan Pharmaceutical experienced a net inflow of 8.03 million yuan from institutional investors, but a net outflow of 9.69 million yuan from retail investors [3]

Core Viewpoint - Tai Long Pharmaceutical (600222) has announced the use of idle self-owned funds for entrusted wealth management, aiming to invest up to 250 million yuan in low-risk financial products to enhance returns while ensuring fund safety [1] Group 1: Stock Performance - As of December 30, 2025, Tai Long Pharmaceutical's stock closed at 6.66 yuan, up 1.52% from the previous trading day, with a total market capitalization of 3.822 billion yuan [1] - The stock opened at 6.55 yuan, reached a high of 6.77 yuan, and a low of 6.50 yuan, with a trading volume of 1.55 billion yuan and a turnover rate of 4.08% [1] Group 2: Wealth Management Announcement - The company held its sixth meeting of the tenth board of directors on December 30, 2025, where it approved the use of no more than 250 million yuan of idle self-owned funds for entrusted wealth management [1] - The investment will focus on low-risk financial products provided by listed financial institutions, including bank wealth management, money market funds, and reverse repos, with a single term not exceeding 6 months [1] - The wealth management period is set for within 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] - This matter does not require submission for shareholder meeting approval, and the company has established relevant risk control measures to ensure fund safety without affecting the normal operation of its main business [1]